480 related articles for article (PubMed ID: 27754367)
1. The Last Ten Years of Advancements in Plant-Derived Recombinant Vaccines against Hepatitis B.
Joung YH; Park SH; Moon KB; Jeon JH; Cho HS; Kim HS
Int J Mol Sci; 2016 Oct; 17(10):. PubMed ID: 27754367
[TBL] [Abstract][Full Text] [Related]
2. Oral hepatitis B vaccine candidates produced and delivered in plant material.
Streatfield SJ
Immunol Cell Biol; 2005 Jun; 83(3):257-62. PubMed ID: 15877603
[TBL] [Abstract][Full Text] [Related]
3. The comparison of antibody response to different hepatitis b vaccines with and without pre-S2 antigen in children with cancer.
Emir S; Büyükpamuk M; Akyüz C; Kutluk T; Güler E; Cağlar K
Pediatr Hematol Oncol; 2002 Jun; 19(4):227-33. PubMed ID: 12051588
[TBL] [Abstract][Full Text] [Related]
4. Do we need better hepatitis B vaccines?
Gerlich WH
Indian J Med Res; 2017 Apr; 145(4):414-419. PubMed ID: 28862172
[No Abstract] [Full Text] [Related]
5. Hepatitis B vaccine effectiveness in the face of global HBV genotype diversity.
Cassidy A; Mossman S; Olivieri A; De Ridder M; Leroux-Roels G
Expert Rev Vaccines; 2011 Dec; 10(12):1709-15. PubMed ID: 22085174
[TBL] [Abstract][Full Text] [Related]
6. Hepatitis B vaccines: protective efficacy and therapeutic potential.
Michel ML; Tiollais P
Pathol Biol (Paris); 2010 Aug; 58(4):288-95. PubMed ID: 20382485
[TBL] [Abstract][Full Text] [Related]
7. Cloning, protein expression and immunogenicity of HBs-murine IL-18 fusion DNA vaccine.
Channarong S; Mitrevej A; Sinchaipanid N; Usuwantim K; Kulkeaw K; Chaicumpa W
Asian Pac J Allergy Immunol; 2007 Dec; 25(4):233-42. PubMed ID: 18402297
[TBL] [Abstract][Full Text] [Related]
8. Hepatitis B virus vaccine breakthrough infection: surveillance of S gene mutants of HBV.
Qin Y; Liao P
Acta Virol; 2018; 62(2):115-121. PubMed ID: 29895151
[TBL] [Abstract][Full Text] [Related]
9. Plant-based vaccines against human hepatitis B virus.
Shchelkunov SN; Shchelkunova GA
Expert Rev Vaccines; 2010 Aug; 9(8):947-55. PubMed ID: 20673016
[TBL] [Abstract][Full Text] [Related]
10. [Oral vaccines--a future prospect! Hepatitis vaccination in the vegetable market?].
Stiefelhagen P
MMW Fortschr Med; 2003 Nov; 145(47):10. PubMed ID: 14725025
[No Abstract] [Full Text] [Related]
11. Production of hepatitis B surface antigen in recombinant plant systems: an update.
Kumar GB; Ganapathi TR; Bapat VA
Biotechnol Prog; 2007; 23(3):532-9. PubMed ID: 17348684
[TBL] [Abstract][Full Text] [Related]
12. Low-dose oral immunization with lyophilized tissue of herbicide-resistant lettuce expressing hepatitis B surface antigen for prototype plant-derived vaccine tablet formulation.
Pniewski T; Kapusta J; Bociąg P; Wojciechowicz J; Kostrzak A; Gdula M; Fedorowicz-Strońska O; Wójcik P; Otta H; Samardakiewicz S; Wolko B; Płucienniczak A
J Appl Genet; 2011 May; 52(2):125-36. PubMed ID: 21107787
[TBL] [Abstract][Full Text] [Related]
13. A novel, recombinant triple antigen hepatitis B vaccine (Hepacare).
Page M; Jones CD; Bailey C
Intervirology; 2001; 44(2-3):88-97. PubMed ID: 11509870
[TBL] [Abstract][Full Text] [Related]
14. Safety, immunization coverage and determinants of a new kind of Hepatitis B vaccine firstly applied in Ningbo, China.
Yang S; Ma X; Ni H; Zhou S; Hu D; Shi H; Chen X; Dong H; Xu G
Hum Vaccin Immunother; 2015; 11(12):2819-26. PubMed ID: 26211419
[TBL] [Abstract][Full Text] [Related]
15. A novel chimeric Hepatitis B virus S/preS1 antigen produced in mammalian and plant cells elicits stronger humoral and cellular immune response than the standard vaccine-constituent, S protein.
Dobrica MO; Lazar C; Paruch L; Skomedal H; Steen H; Haugslien S; Tucureanu C; Caras I; Onu A; Ciulean S; Branzan A; Clarke JL; Stavaru C; Branza-Nichita N
Antiviral Res; 2017 Aug; 144():256-265. PubMed ID: 28666757
[TBL] [Abstract][Full Text] [Related]
16. Expression and immunoactivity of chimeric particulate antigens of receptor binding site-core antigen of hepatitis B virus.
Yang HJ; Chen M; Cheng T; He SZ; Li SW; Guan BQ; Zhu ZH; Gu Y; Zhang J; Xia NS
World J Gastroenterol; 2005 Jan; 11(4):492-7. PubMed ID: 15641132
[TBL] [Abstract][Full Text] [Related]
17. Safety of currently licensed hepatitis B surface antigen vaccines in the United States, Vaccine Adverse Event Reporting System (VAERS), 2005-2015.
Haber P; Moro PL; Ng C; Lewis PW; Hibbs B; Schillie SF; Nelson NP; Li R; Stewart B; Cano MV
Vaccine; 2018 Jan; 36(4):559-564. PubMed ID: 29241647
[TBL] [Abstract][Full Text] [Related]
18. Improvement of hepatitis B virus DNA vaccines by plasmids coexpressing hepatitis B surface antigen and interleukin-2.
Chow YH; Huang WL; Chi WK; Chu YD; Tao MH
J Virol; 1997 Jan; 71(1):169-78. PubMed ID: 8985336
[TBL] [Abstract][Full Text] [Related]
19. Recombinant versus plasma-derived hepatitis B vaccines: issues of safety, immunogenicity and cost-effectiveness.
Stephenne J
Vaccine; 1988 Aug; 6(4):299-303. PubMed ID: 2973187
[TBL] [Abstract][Full Text] [Related]
20. The heritage of hepatitis B vaccine.
Douglas RG
JAMA; 1996 Dec; 276(22):1796-8. PubMed ID: 8946890
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
